RCC: Tivozanib beats sorafenib in later lines

In TIVO-3, a phase 3 trial involving 350 patients with metastatic RCC who had been treated with two or more systemic therapies, patients in the tivozanib group had significantly longer PFS versus sorafenib.

Read the full article here

Related Articles